JP2019523001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523001A5 JP2019523001A5 JP2019503538A JP2019503538A JP2019523001A5 JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5 JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- transduced
- culturing
- heterologous nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366493P | 2016-07-25 | 2016-07-25 | |
| US62/366,493 | 2016-07-25 | ||
| PCT/US2017/043774 WO2018022646A1 (en) | 2016-07-25 | 2017-07-25 | Methods of producing modified natural killer cells and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523001A JP2019523001A (ja) | 2019-08-22 |
| JP2019523001A5 true JP2019523001A5 (enExample) | 2020-08-06 |
| JP7086928B2 JP7086928B2 (ja) | 2022-06-20 |
Family
ID=59656171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503538A Active JP7086928B2 (ja) | 2016-07-25 | 2017-07-25 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11293010B2 (enExample) |
| EP (2) | EP3487991B1 (enExample) |
| JP (2) | JP7086928B2 (enExample) |
| CN (2) | CN109844099B (enExample) |
| IL (1) | IL273979B2 (enExample) |
| SG (2) | SG11201810871WA (enExample) |
| WO (2) | WO2018022646A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| US12516292B2 (en) | 2016-07-25 | 2026-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| EP3487991B1 (en) | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| WO2018104554A1 (en) * | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| JP7360174B2 (ja) * | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| SG11202008008UA (en) * | 2018-02-21 | 2020-09-29 | Univ Texas | Universal antigen presenting cells and uses thereof |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| CN112512573B (zh) * | 2018-05-23 | 2026-02-27 | 百提威生技股份有限公司 | 双特异性t细胞衔接蛋白及其用途 |
| US12304962B2 (en) | 2018-05-30 | 2025-05-20 | Glycostem Therapeutics B.V. | CAR NK cells |
| US12692308B2 (en) | 2018-06-06 | 2026-07-28 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for cell enrichment |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| SG11202102012SA (en) * | 2018-08-28 | 2021-04-29 | Pharos Vaccine Inc | Improved lentiviral vector |
| KR20210063348A (ko) * | 2018-08-28 | 2021-06-01 | 이뮤노테크 바이오팜 씨오., 엘티디. | 개선된 치료용 t 세포 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
| EP3864160A4 (en) * | 2018-10-10 | 2022-10-26 | Wisconsin Alumni Research Foundation | KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME |
| CN109402053A (zh) * | 2018-10-17 | 2019-03-01 | 广州元帅生物科技有限公司 | 一种外周血来源单个核细胞的分离及诱导培养方法 |
| EP3884041A2 (en) * | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| CN113710691B (zh) | 2019-02-20 | 2025-03-04 | 罗格斯新泽西州立大学 | 自然杀伤和嵌合抗原受体修饰的细胞的扩增 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| KR20200110576A (ko) * | 2019-03-15 | 2020-09-24 | 재단법인대구경북과학기술원 | 사이토카인 기반 면역세포 및 그의 면역 치료 용도 |
| CN113710697A (zh) | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| EP3712257A1 (en) * | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| JP2022526504A (ja) * | 2019-03-21 | 2022-05-25 | オーエヌケー セラピューティクス リミテッド | 細胞死に対する耐性が増大した改変免疫エフェクター細胞 |
| CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
| CN110106202A (zh) * | 2019-05-07 | 2019-08-09 | 杭州师范大学 | 抗肿瘤nk细胞的制备方法及其细胞与应用 |
| CA3143198A1 (en) * | 2019-06-14 | 2020-12-17 | G Tech Bio Llc | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions |
| CN110205293A (zh) * | 2019-06-25 | 2019-09-06 | 中冠赛尔生物科技(北京)有限公司 | 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用 |
| US20210077527A1 (en) * | 2019-09-13 | 2021-03-18 | The Research Institute At Nationwide Children's Hospital | Universal donor selection method to identify nk-cell-donors |
| US20220347216A1 (en) * | 2019-09-13 | 2022-11-03 | Ohio State Innovation Foundation | Nk cell immunotherapy compositions, methods of making and methods of using same |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| AU2020437669A1 (en) | 2020-03-26 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD28H domain-containing chimeric antigen receptors and methods of use |
| CN113528452B (zh) * | 2020-07-06 | 2023-06-06 | 上海鑫湾生物科技有限公司 | 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用 |
| IL300903A (en) * | 2020-09-02 | 2023-04-01 | Nkarta Inc | Expansion and enhanced cytotoxicity of natural killer cells and their uses |
| EP3964265A1 (en) * | 2020-09-07 | 2022-03-09 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof |
| CN112029721A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种活性增强型nk细胞的制备方法 |
| KR102581230B1 (ko) * | 2020-10-16 | 2023-09-21 | 의료법인 성광의료재단 | 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도 |
| EP4240829A1 (en) | 2020-11-04 | 2023-09-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Modified nk cells with reduced ccr5 expression and methods of their use |
| US20240197783A1 (en) * | 2021-04-21 | 2024-06-20 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| CA3228692A1 (en) * | 2021-08-30 | 2023-03-09 | Edward L. Perkins | Tcd34 and other markers for identification and sorting of cells and for use as in vivo tracking assistant |
| WO2023044304A1 (en) | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN114381434A (zh) * | 2022-01-17 | 2022-04-22 | 华东师范大学 | 一种趋化型car-nk细胞及其制备方法和应用 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| CN115074325A (zh) * | 2022-07-07 | 2022-09-20 | 广州希灵生物科技有限公司 | Herceptin联合4-1BBL体外扩增NK方法 |
| CN115466726B (zh) * | 2022-09-05 | 2023-09-19 | 北京景达生物科技有限公司 | 一种nk细胞的高效基因转导方案 |
| CN116178566A (zh) * | 2022-09-30 | 2023-05-30 | 深圳博雅感知药业有限公司 | 靶向cd33的嵌合抗原受体和制备b16-cd33 car-nk细胞的方法 |
| CN115975922B (zh) * | 2022-12-15 | 2024-06-28 | 杭州师范大学 | Bx795在制备nk-92细胞激活剂上的应用 |
| WO2024131685A1 (zh) * | 2022-12-19 | 2024-06-27 | 苏州沙砾生物科技有限公司 | 一种细胞培养方法及其用途 |
| WO2024261045A1 (en) | 2023-06-20 | 2024-12-26 | Zelluna Immunotherapy As | Methods of enhancing or modifying nk cells |
| WO2025232819A1 (en) * | 2024-05-08 | 2025-11-13 | Qihan Hong Kong Limited | Immunotherapies using engineered cells for enhanced bone marrow homing |
| EP4692325A1 (en) * | 2024-08-07 | 2026-02-11 | Miltenyi Biotec B.V. & Co. KG | Method for generation of a composition comprising natural killer cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| JP5525689B2 (ja) | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| CN101356679A (zh) * | 2005-10-31 | 2009-01-28 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
| US20070264687A1 (en) * | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| CN101684456A (zh) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | 一种体外培养条件下扩增人nk细胞的方法 |
| EP3546583A1 (en) * | 2009-06-17 | 2019-10-02 | Tocagen Inc. | Producer cells for replication competent retroviral vectors |
| RU2729401C2 (ru) * | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| EP2793026A1 (en) * | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| DK2992020T3 (da) * | 2013-05-03 | 2020-02-10 | Ohio State Innovation Foundation | Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| WO2016085946A1 (en) * | 2014-11-24 | 2016-06-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Active cxcr4+ immune cells and methods for their production and use |
| US12533338B2 (en) * | 2015-09-30 | 2026-01-27 | Vycellix, Inc. | Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages |
| CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
| EP3487991B1 (en) | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| US12516292B2 (en) * | 2016-07-25 | 2026-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| CN106350487B (zh) * | 2016-09-13 | 2019-01-25 | 北京多赢时代转化医学研究院 | 联合制备car-nk细胞和car-nkt细胞的方法 |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
-
2017
- 2017-07-25 EP EP17754517.5A patent/EP3487991B1/en active Active
- 2017-07-25 JP JP2019503538A patent/JP7086928B2/ja active Active
- 2017-07-25 WO PCT/US2017/043774 patent/WO2018022646A1/en not_active Ceased
- 2017-07-25 SG SG11201810871WA patent/SG11201810871WA/en unknown
- 2017-07-25 CN CN201780046354.1A patent/CN109844099B/zh active Active
- 2017-11-01 US US15/801,085 patent/US11293010B2/en active Active
-
2018
- 2018-11-01 WO PCT/US2018/058747 patent/WO2019089955A1/en not_active Ceased
- 2018-11-01 CN CN201880071474.1A patent/CN111344395B/zh active Active
- 2018-11-01 JP JP2020524196A patent/JP7364559B2/ja active Active
- 2018-11-01 EP EP18811415.1A patent/EP3704231A1/en active Pending
- 2018-11-01 SG SG11202003201QA patent/SG11202003201QA/en unknown
- 2018-11-01 IL IL273979A patent/IL273979B2/en unknown
-
2022
- 2022-03-07 US US17/688,435 patent/US12448604B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501578A5 (enExample) | ||
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Meng et al. | Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells | |
| JP7778708B2 (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
| IL273979B2 (en) | Methods of producing modified natural killer cells and methods of use | |
| JP2022130607A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| CN114761027A (zh) | 用于免疫细胞扩增的Cbl抑制剂和组合物 | |
| Murad et al. | Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy | |
| JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| JP2021522839A5 (enExample) | ||
| Zhang et al. | Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS− regulatory T cells | |
| CN115768879A (zh) | 用于培养细胞的方法 | |
| JP2022542321A (ja) | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 | |
| Shook et al. | Natural killer cell engineering for cellular therapy of cancer | |
| Xu et al. | Cellular immunotherapy for hematological malignancy: recent progress and future perspectives | |
| CN113785048B (zh) | 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法 | |
| Ye et al. | Folate Receptor‐Alpha Targeted 7x19 CAR‐γδT Suppressed Triple‐Negative Breast Cancer Xenograft Model in Mice | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| JP2018531016A5 (enExample) | ||
| Payne et al. | Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy | |
| Wang et al. | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context | |
| Fukuta et al. | Cell therapies against brain tumors: Clinical development and emerging prospects | |
| Han et al. | Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies |